Zobrazeno 1 - 4
of 4
pro vyhledávání: '"I V Ishmatova"'
Autor:
M S Motalkina, S A Kulyova, S M Alexeev, I S Zuzgin, L V Filatova, A S Zhabina, A A Zverkova, I V Ishmatova, A A Rjazankina, A S Artemyeva, T Yu Semiglazova
Publikováno v:
Современная онкология, Vol 17, Iss 2, Pp 54-56 (2015)
In our clinical example, we studied the possibility of early treatment intensification, through the use of a new combination pegfilgrastim and plerixafor as a regime of mobilization. Within 4 days (after a single injection pegfilgrastim 6 mg in D1) w
Externí odkaz:
https://doaj.org/article/6597e0dcba3e4b39b7faf3c59ad667c7
Autor:
A. A. Mamedova, N. E. Mochkin, V. O. Sarzhevskiy, E. A. Demina, V. S. Bogatyrev, A. A. Spornik, A. A. Samoylova, A. A. Rukavitsin, E. G. Smirnova, A. E. Bannikova, V. Ya. Melnichenko, N. B. Mikhaylova, E. S. Borzenkova, L. V. Stelmakh, Yu. R. Zalyalov, A. A. Semenova, G. S. Tumyan, M. A. Danilova, O. A. Konova, N. A. Falaleeva, A. Yu. Terekhova, M. A. Vernyuk, A. M. Chervontseva, L. S. Khayrullina, A. A. Maslov, I. B. Lysenko, Yu. A. Alekseeva, E. S. Pavlyuchenko, A. A. Mirsaitov, A. A. Zverkova, I. V. Ishmatova, S. A. Volchenkov, M. S. Motalkina, I. S. Zyuzgin
Publikováno v:
Онкогематология, Vol 17, Iss 3, Pp 40-47 (2022)
Aim. To study the efficacy and safety of combined immunochemotherapy according to the DHAp protocol + nivolumab in patients with refractory/relapsed classical Hodgkin's lymphoma before autologous hematopoietic stem cell transplantation.Materials and
Externí odkaz:
https://doaj.org/article/61dd8e7c89fc477eb1ba03f4c408b04b
Autor:
A. K. Koviazin, L. V. Filatova, I. S. Zyuzgin, A. S. Artemyeva, M. S. Motalkina, Yu. A. Chudinovskikh, E. V. Dobrovolskaya, S. A. Volchenkov, I. L. Polyatskin, S. A. Shalaev, I. V. Ishmatova, A. A. Zverkova, D. S. Burda, S. S. Elkhova, T. Yu. Semiglazova
Publikováno v:
Медицинский совет, Vol 0, Iss 9, Pp 104-116 (2022)
Introduction. Diffuse large B-cell lymphoma (DLBCL) is the most common (30-35%) type of B-cell lymphomas. Only about 60% of all newly diagnosed advanced-stage DLBCL can be completely treated by x6 CHOP-R only. High dose chemotherapy (HDCT) followed b
Externí odkaz:
https://doaj.org/article/9e2cca6dd1294807a4aa309975c44b15
Autor:
L V, Filatova, S M, Alekseev, I S, Zyuzgin, A S, Zhabina, M S, Motalkina, A A, Zverkova, I V, Ishmatova, N A, Kotova, A A, Chudinovskikh, D A, Zvyaginsteva, U B, Khadonov, T Yu, Semiglazova
Publikováno v:
Voprosy onkologii. 62(2)
Using of radiochemotherapy improves short-term and long-term results of treatment in patients with primary Hodgkin’s lymphoma (HL) comparing with treatment by chemotherapy alone. The rates of 5-year, 10-year OS and DFS are 88%, 83% and 90%, 86% in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f0c28e593b8ada889355229fb2ce0fb0
https://pubmed.ncbi.nlm.nih.gov/30462433
https://pubmed.ncbi.nlm.nih.gov/30462433